Key result
Transcatheter therapies for severe TR show promise for improving safety, TR severity, and quality of life.
Why the study?
Severe tricuspid regurgitation confers an adverse prognosis, driving the development of transcatheter therapies in patients considered high risk for surgery.
Transcatheter therapies such as TEER represent a promising, safe alternative for reducing TR severity and improving quality of life in patients at high surgical risk.
Observational data support further study of transcatheter TR therapies in high-risk patients; should not yet change practice without randomized trials.
It is now widely recognized that severe tricuspid regurgitation (TR) confers an adverse prognosis and accordingly, the emphasis has shifted from ignoring TR to developing transcatheter therapies in patients for whom surgery is considered high risk. These options largely involve annuloplasty, transcatheter edge-to-edge repair (TEER), or transcatheter tricuspid valve replacement (TTVR), although other methods have also been attempted. Multiple observational studies have shown great promise for these procedures with regard to safety, reduction of TR severity and associated improvements in quality of life.
No takes yet. Share an insight, caveat, or question.
Paul Grayburn (2021) conducted a review in Severe tricuspid regurgitation. Transcatheter therapies (including TEER, TTVR, and annuloplasty) was evaluated. Transcatheter therapies for severe tricuspid regurgitation, including edge-to-edge repair, show promise in observational studies for improving safety, TR severity, and quality of life.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: